This study was designed to determine the association of CP2C19*2 loss of function polymorphism with acute coronary syndrome patients receiving clopidogrel. After getting informed consent signed by the participants, 5ml of intravenous blood was collected from 112 acute coronary syndrome patients and 105 healthy controls. CYP2C19*2 genetic polymorphism was determined by polymerase chain reaction followed by restriction fragment length polymorphism. The frequency of CP2C19*2 heterozygous GA was 38.3%, homozygous (wild type) GG was 58.7% and homozygous (mutant) AA was 3.4% in patients while in control subjects the frequency of heterozygous GA was 29.5%, homozygous GG was 59.0% and homozygous AA was 11.4% (p= 0.3513, OR 1.2927, 95% CI 0.75-2.21). The result shows no statistical significance in terms of the distribution of this genetic polymorphism between acute coronary syndrome patients and control individuals. These results suggest that the CYP2C19*2 loss of function polymorphism is not associated with acute coronary syndrome in this Pakistani cohort